EVI5L

Across TCGA pan-cancer cohorts, EVI5L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EVI5L data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EVI5L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EVI5L expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where EVI5L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.883	0.622	.008	23	view →
PDAC	DFS	Quartile	All	0.262	0.467	.019	14	view →
LSCC	DFS	Quartile	III,IV	0.407	0.913	.003	7	view →
GBM	DFS	Quartile	All	0.289	0.603	.019	6	view →
UCEC	OS	Tertile	III,IV	0.281	1.000	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EVI5L–CCRCC (OS)

Open the CCRCC breakdown →